A Hospital-Based Registry of Preventive Cardiology Clinics (PREVENT-CARD)

Assessment and Control of Modifiable Risk Factors for Primary and Secondary Prevention

More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.

Study Overview

• Status: Recruiting
• Conditions: Cardiovascular Morbidity; Cardiovascular Risk Assesment; Primary Prevention CVD
• Intervention / Treatment: Other: Cardiovascular risk assesment

Detailed Description

Study Design: observational study Duration of Study: ongoing. Sample Size: All patients presenting to preventive cardiology clinics at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan..

Sampling Technique: Non-probability consecutive sampling Data Collection Procedure: Verbal informed consent will be obtained from all the patients regarding their participation in the study and publication of study findings while maintaining confidentiality. Consecutive patients presenting preventive cardiology clinics at the National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan, will be included in this registry. Demographic characteristics, physical examination, clinical history, risk modification, lab assessment, and ASCVD risk score at presentation and at every follow-up will be recorded using a structural questionnaire.

Data Analysis Procedure: The Tentative analysis plan uses collected data for research publications. The statistical package for social sciences (SPSS 21) will be used to analyze baseline characteristics. The Shapiro-Wilk test will be applied to check the hypothesis of normality for quantitative (continuous) variables. Descriptive statistics such as mean ± SD, median (IQR), skewness, maximum, and minimum will be calculated for quantitative (continuous) variables. Frequency and percentages will be calculated for categorical variables.

• Study Type: Observational
• Enrollment (Estimated): 10000

Contacts and Locations

• Study Contact: Name: Dr Rubina Rauf; Phone Number: +923002947117; Email: drrubinarauf@gmail.com
• Study Contact Backup: Name: Musa Karim; Phone Number: +923323646169; Email: mkarim.nicvd@gmail.com

Study Locations

• Pakistan
  • Sindh
    • Karachi, Sindh, Pakistan, 75510
      • Recruiting
      • National Institute of Cardiovascular Diseases
      • Contact: Dr Rubina Rauf; Phone Number: +923002947117; Email: drrubinarauf@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Both genders, age 18 and above, visiting preventive cardiology clinics with or without established CVD and may or may not have CVD risk factors.

Description

Inclusion Criteria:

• All individuals attending the preventive cardiology clinics.

Exclusion Criteria:

• • Individuals who refused to give consent.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Adult patients; Adult patients with or without cardiovascular diseases.	Other: Cardiovascular risk assesment; ASCVD Score and WHO Cardiovascular Risk score.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
cardiovascular risk assesesment	risk stratification of Cardiovascular diseases (CVD) in patients without established CVD but with CVD co morbids.we are using Atherosclerotic Cardiovascular Diseases (ASCVD) Risk Score and World Heart Organization(WHO) Risk Score for CVD Risk Assesment. In ASCVD Risk Score, we categorize population into low risk ( score <5), borderline(score between 5 and 7.4) ,intermediate( score between 7.5 an 19.9) and high risk (score>20), using all parameters for risk assesment. For WHO risk score calculation we are using WHO Risk score system for South Asia. https://cdn.who.int/media/docs/default-source/cardiovascular-diseases/south-asia.pdf?sfvrsn=c5b0d9a3_2	Ten years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cardiovascular risk reduction	CVD risk reduction in patients with or without established CVD but with CVD co morbids.	Ten years
Cardiovascular related deaths	Estimation of patients who expired in their follow up despite CVD risk factors management.	Ten years.

Collaborators and Investigators

• Sponsor: National Institute of Cardiovascular Diseases, Pakistan
• Investigators: Principal Investigator: Dr Rubina Rauf, National Institute of Cardiovascular Diseases

Publications and helpful links

General Publications

• Rauf R, Khan MN, Sial JA, Qamar N, Saghir T, Kazmi KA. Primary prevention of cardiovascular diseases among women in a South Asian population: a descriptive study of modifiable risk factors. BMJ Open. 2024 Nov 14;14(11):e089149. doi: 10.1136/bmjopen-2024-089149.

Study record dates

Study Major Dates

• Study Start (Actual): June 17, 2021
• Primary Completion (Estimated): June 1, 2031
• Study Completion (Estimated): June 1, 2041

Study Registration Dates

• First Submitted: July 9, 2024
• First Submitted That Met QC Criteria: July 9, 2024
• First Posted (Actual): July 16, 2024

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 9, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: IRB-20/2023

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No